Kovatchev B, Clarke W. Peculiarities of the continuous glucose monitoring data stream and their impact on developing closed-loop control technology. J Diabetes Sci Technol 2008;2(1):158–163
18. Saur NM, Kongable GL, Holewinski S, O’Brien K, Nasraway SA, Jr. Software-guided insulin dosing: tight glycemic control and decreased glycemic derangements in critically ill patients. Mayo Clin Proc 2013;88(9):920–929
19. Umpierrez GE, Gianchandani R, Smiley D, Jacobs S, Wesorick DH, Newton C, et al. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study. Diabetes Care 2013;36(11):3430–3435
20. Umpierrez GE, Schwartz S. Use of incretin-based therapy in hospitalized patients with hyperglycemia. Endocr Pract 2014;20(9):933–944
21. Arnold P, Paxton RA, McNorton K, Szpunar S, Edwin SB. The effect of a hypoglycemia treatment protocol on glycemic variability in critically ill patients. J Intensive Care Med 2015;30(3):156–160
22. Barassi A, Umbrello M, Ghilardi F, Damele CA, Massaccesi L, Iapichino G, et al. Evaluation of the performance of a new OptiScanner 5000 system for an intermittent glucose monitoring. Clin Chim Acta 2015;438:252–254
23. Schwartz SS, DeFronzo RA, Umpierrez GE. Practical implementation of incretin-based therapy in hospitalized patients with type 2 diabetes. Postgrad Med 2015;127(2):251–257
24. Diabetes Control and Complications Trial Research Group (DCCT). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986
25. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131):837–853
26. Ellenberg M. Diabetic neuropathy precipitating after institution of diabetic control. Am J Med Sci 1958;236(4):466–471
27. Oyibo SO, Prasad YD, Jackson NJ, Jude EB, Boulton AJ. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet Med 2002;19(10):870–873
28. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005;28(4):956–962
29. Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005;352(4):341–350
30. Gibbons CH, Freeman R. Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy. Ann Neurol 2010;67(4):534–541
31. Diabetes Control and Complications Trial Research Group (DCCT). Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998;116(7):874–886
32. Aiello LP. Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014;37(1):17–23
33. Gerstein HC, Miller ME, Byington RP, Goff DC, Jr., Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358(24):2545–2559
34. Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010;33(5):983–990
35. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38(1):140–149
36. Moghissi E, Inzucchi S. The Evolution of Glycemic Control in the Hospital Setting. In Managing Diabetes and Hyperglycemia in the Hospital Setting. Draznin, B, Ed. Alexandria, VA, American Diabetes Association, 2016, p. 1–10
37. Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. Lancet 2009;373(9677):1798–1807
38. Kotagal M, Symons RG, Hirsch IB, Umpierrez GE, Dellinger EP, Farrokhi ET, et al. Perioperative hyperglycemia and risk of adverse events among patients with and without diabetes. Ann Surg 2015;261(1):97–103
39. Dhatariya K, Levy N, Kilvert A, Watson B, Cousins D, Flanagan D, et al. NHS Diabetes guideline for the perioperative management of the adult patient with diabetes. Diabet Med 2012;29(4):420–433
40. Umpierrez GE, Smiley D, Jacobs S, Peng L, Temponi A, Mulligan P, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care 2011;34(2):256–261
41. Draznin B, Wang Y, Seggelke S, Hawkins RM, Gibbs J, Bridenstine M, et al. Glycemic control and outcomes of hospitalization in noncritically ill patients with type 2 diabetes admitted with cardiac problems or infections. Endocr Pract 2014;20(12):1303–1308
42. Murphy CV, Coffey R, Wisler J, Miller SF. The relationship between acute and chronic hyperglycemia and outcomes in burn injury. J Burn Care Res 2013;34(1):109–114
43. Siegelaar SE, Hickmann M, Hoekstra JB, Holleman F, DeVries JH. The effect of diabetes on mortality in critically ill patients: a systematic review and meta-analysis. Crit Care 2011;15(5):R205
44. Esper AM, Moss M, Martin GS. The effect of diabetes mellitus on organ dysfunction with sepsis: an epidemiological study. Crit Care 2009;13(1):R18
45. Stegenga ME, Vincent JL, Vail GM, Xie J, Haney DJ, Williams MD, et al. Diabetes does not alter mortality or hemostatic and inflammatory responses in patients with severe sepsis. Crit Care Med 2010;38(2):539–545
46. Vincent JL, Preiser JC, Sprung CL, Moreno R, Sakr Y. Insulin-treated diabetes is not associated with increased mortality in critically ill patients. Crit Care 2010;14(1):R12
47. Schlussel AT, Holt DB, Crawley EA, Lustik MB, Wade CE, Uyehara CF. Effect of diabetes mellitus on outcomes of hyperglycemia in a mixed medical surgical intensive care unit. J Diabetes Sci Technol 2011;5(3):731–740
48. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002;87(3):978–982
49. Rady MY, Johnson DJ, Patel BM, Larson JS, Helmers RA. Influence of individual characteristics on outcome of glycemic control in intensive care unit patients with or without diabetes mellitus. Mayo Clin Proc 2005;80(12):1558–1567
50. Whitcomb BW, Pradhan EK, Pittas AG, Roghmann MC, Perencevich EN. Impact of admission hyperglycemia on hospital mortality in various intensive care unit populations. Crit Care Med 2005;33(12):2772–2777
51. Krinsley JS. Glycemic control, diabetic status, and mortality in a heterogeneous population of critically ill patients before and during the era of intensive glycemic management: six and one-half years experience at a university-affiliated community hospital. Semin Thorac Cardiovasc
